On August 4, 2022, Gilead Sciences and MiroBio, a privately-held UK-based biotechnology company focused on restoring immune balance with agonists targeting immune inhibitory receptors, announced that the companies have entered into a definitive agreement pursuant to which Gilead will acquire MiroBio for approximately $405 million in cash, subject to customary adjustments. The acquisition will provide Gilead with MiroBio’s proprietary discovery platform and entire portfolio of immune inhibitory receptor agonists. MiroBio’s lead investigational antibody, MB272, is a selective agonist of immune inhibitory receptor B- and T-Lymphocyte Attenuator (BTLA) and has entered Phase 1 clinical trials, with the first patient dosed earlier this week. MB272 targets T, B and dendritic cells to inhibit or blunt activation and suppress an inflammatory immune response.

A Wilson Sonsini Goodrich & Rosati team led by Lou Lieto, Tom Owens, and Wei Huang advised MiroBio on patent matters related to the acquisition. The firm has counseled MiroBio on all patents and innovations matters since MiroBio's formation.

For more information, please see the press release.